Parkinson disease and growth factors — is GDNF good enough?

Research output: Contribution to journalDebate/Note/Editorial

Abstract

Previous open-label trials testing glial cell line-derived neurotrophic factor (GDNF) family ligands in Parkinson disease have shown promising clinical effects. However, in placebo-controlled trials, the treatments have failed. A new randomized placebo-controlled trial of intraputamenal delivery of GDNF designed to resolve this conundrum has again failed to do just that.

Details

Authors
Organisations
External organisations
  • University of Cambridge
  • University of Copenhagen
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurosciences
Original languageEnglish
Pages (from-to)312
Number of pages314
JournalNature Reviews Neurology
Volume15
Publication statusPublished - 2019 Apr 4
Publication categoryResearch
Peer-reviewedYes